Table of Contents
CBDV — short for cannabidivarin — is a rare cannabinoid that looks almost identical to CBD, with one small chemical difference: a shorter side chain. It is non-intoxicating, it was once a promising epilepsy candidate, and its biggest human trial failed. That failure is the most honest and most interesting part of its story.
What exactly is CBDV?
CBDV is a naturally occurring minor cannabinoid in Cannabis sativa, usually present only in trace amounts. It was first isolated in 1969, then sat largely unstudied for decades while CBD and THC took the spotlight. It only came back into focus when GW Pharmaceuticals — the company behind the CBD epilepsy drug Epidiolex — picked it up as a drug candidate.
Chemically, CBDV is the propyl homologue of CBD. Both share the same core structure, but CBD carries a five-carbon pentyl side chain while CBDV carries a three-carbon propyl one — two carbons shorter. Its formula is C19H26O2, with a molecular weight of about 286, compared with about 314 for CBD. Like CBD, CBDV starts life in the plant as an acidic precursor, CBDVA, which converts to CBDV when heated.
That shorter tail is the same change that separates THCV from THC, and it matters more than it sounds. A two-carbon difference can change how a molecule fits its targets, and CBDV behaves differently from CBD in several lab tests even though the two look like twins on paper.
How is CBDV different from CBD?
The simplest difference is abundance. CBD is a major cannabinoid, present in large amounts in hemp and CBD-rich cannabis. CBDV is a trace compound, found in meaningful amounts mainly in certain landrace strains — older, regional varieties from parts of Asia and Africa, including indica-dominant landraces from north-west India and hashish-producing regions of Nepal and Pakistan — and in some CBD-rich hemp cultivars.
The second difference is what it does at receptors. Like CBD, CBDV has little to no affinity for CB1, the receptor behind the THC high, which is why neither compound is intoxicating. But CBDV has shown demonstrable activity at CB2 receptors, behaving as a partial agonist there, while CBD’s CB2 activity is weaker. CBDV also activates and desensitises TRP channels — TRPV1, TRPV2, and TRPA1 — which are involved in how nerve cells respond to stimuli. CBD touches some of the same channels, but the balance of effects is not the same.
The third difference is the one that matters most: evidence. CBD has an FDA-approved prescription drug, Epidiolex, for certain seizure disorders, backed by large clinical trials. CBDV has no approved drug and no large successful trial. If you are comparing the two, that gap in human evidence is the real story — not the chemistry.
Does CBDV get you high?
No. Like CBD, CBDV does not meaningfully activate CB1 receptors, so it does not produce a high. That puts it in the same non-intoxicating family as CBD and CBG, the “mother cannabinoid” that starts the plant’s cannabinoid production line. It is also why CBDV has been studied as a possible medicine rather than as a recreational compound — researchers were interested in what it might do in the brain without intoxication.
That said, non-intoxicating does not mean inactive. CBDV acts on the central nervous system in lab models, and it is a drug under investigation, not a supplement with a settled safety record. “Does not get you high” is not the same as “safe for everyone,” and that distinction matters for anything being tested as a medicine.
What did the epilepsy research find?
This is where CBDV’s story gets honest — and a little sad. In animals, the early results were strong. A 2012 study by Hill and colleagues showed CBDV was anticonvulsant in both mouse and rat seizure models, and a 2013 study by Amada and colleagues found it suppressed seizure-related changes in gene expression. On that basis, GW Pharmaceuticals developed CBDV as GWP42006 and took it into human trials for epilepsy.
Then the pivotal trial failed. A randomised, placebo-controlled Phase 2a trial in 162 adults with poorly controlled focal seizures found that GWP42006 did not separate from placebo on its primary endpoint: seizure frequency fell by about 40% in both the CBDV group and the placebo group. The company announced the result in February 2018, and it effectively ended CBDV’s development as a standalone epilepsy drug.
That is a useful lesson, and it is worth saying plainly. CBD and CBDV are near-identical molecules with overlapping mechanisms, yet CBD’s epilepsy trials succeeded and CBDV’s failed. Structural similarity is not clinical equivalence, and a compound that works beautifully in mice can still fail in people. Anyone selling CBDV on the back of CBD’s success is borrowing evidence that does not belong to it.
What about autism and other research?
After the epilepsy trial, research shifted toward autism spectrum disorder and rare neurodevelopmental conditions. The evidence there is preliminary. A small expanded-access pilot at the University of Louisville, in five children and young adults with autism and drug-resistant epilepsy, found CBDV well tolerated at up to 10 mg per kilogram per day over 12 weeks, with caregivers reporting gains in social engagement — but five people and no placebo group cannot prove a treatment works.
A longer open-label safety study in children and young adults with autism (NCT03849456) titrated CBDV to around 10 mg per kilogram per day and looked at communication, social interaction, sleep, behaviour, and cognition. That work has established reasonable safety and tolerability at those doses, but robust efficacy for autism-related outcomes has not been demonstrated. CBDV has also received orphan-drug designations for Rett syndrome and Fragile X syndrome, which are incentives for developing treatments for rare conditions — not proof that it works for them.
Animal research has also explored CBDV for nausea and gut inflammation, including models of intestinal inflammation, but that work is preclinical. As with the epilepsy story, none of it is a reason to use CBDV as a treatment today.
Where can you find CBDV, and is it legal?
CBDV is not something most people will run into. Because it is a trace compound, ordinary cannabis and hemp products contain very little of it, and CBDV-specific products are rare compared with CBD. A lab report on a CBD-rich product may list CBDV among the minor cannabinoids, usually at a fraction of a percent.
Legally, CBDV sits in a grey area that depends on where you are and where it came from. In the United States, cannabinoids derived from hemp are generally treated differently from those derived from marijuana, but the rules vary by state and are still changing, and CBDV has no approved medical use anywhere. This article is general information, not legal advice — check the rules where you live before buying any cannabinoid product.
If you are curious about the wider family of minor cannabinoids, our guides to CBC and THCV — CBDV’s varin cousin on the THC side — cover two more members of the same family, and each one has its own evidence story.
Frequently asked questions
What is CBDV?
CBDV, or cannabidivarin, is a rare, non-intoxicating cannabinoid found in trace amounts in cannabis. It is almost identical to CBD, except its side chain is two carbons shorter — a three-carbon propyl chain instead of CBD’s five-carbon pentyl chain. It was first isolated in 1969 and is best known as a former epilepsy drug candidate.
Is CBDV the same as CBD?
No, though they are close relatives. CBDV shares CBD’s core structure but has a shorter side chain, different activity at CB2 receptors and TRP channels, and far less human evidence. CBD has an FDA-approved drug, Epidiolex, for certain seizure disorders. CBDV has no approved drug, and its biggest epilepsy trial failed to beat placebo.
Does CBDV get you high?
No. Like CBD, CBDV has little to no affinity for CB1, the receptor behind the THC high, so it does not produce intoxication. It is still active in the central nervous system in lab models, though, and it remains an investigational compound — non-intoxicating is not the same as proven safe for everyone.
Can CBDV treat epilepsy or autism?
There is no approved CBDV treatment for either condition. Animal studies looked promising for epilepsy, but a Phase 2a trial in 162 adults with focal seizures failed to beat placebo in 2018. Autism research is still early, with small open-label studies showing tolerability but no proven efficacy. Do not use CBDV as a treatment — talk to your doctor.
Where is CBDV found?
CBDV occurs in trace amounts in most cannabis, and in higher amounts in certain landrace strains from parts of Asia and Africa, including north-west India and hashish-producing regions of Nepal and Pakistan, as well as some CBD-rich hemp cultivars. Ordinary cannabis and hemp products usually contain very little of it.
This article is general information, not medical advice. CBDV is an investigational compound with no approved medical use, and its flagship human trial failed. No cannabinoid product should replace advice from your doctor. If you take prescription medicines or have a health condition, talk to your doctor before using any cannabinoid product. See our medical disclaimer.
For a broader overview of cannabinoid guides on this site, see our THC and cannabinoids hub.
Affiliate Disclosure
The CakeHeights Editorial Team is committed to providing accurate, research-backed information about cannabis and hemp products. Some links on this page are affiliate links, meaning we may earn a commission at no extra cost to you if you make a purchase through them. Our recommendations are based on independent research, testing, and analysis. We only promote products we believe offer genuine value to our readers. Learn more →